Description

RANOL SR 80 MG

Indications

RANOL SR 80 MG is primarily indicated for the management of chronic stable angina pectoris. It is commonly prescribed to patients who have not achieved adequate control of their angina symptoms with other antianginal medications or who are intolerant to those therapies. Additionally, RANOL SR may be used in combination with other medications to enhance therapeutic efficacy in patients with coronary artery disease.

Mechanism of Action

The active ingredient in RANOL SR, ranolazine, functions through a unique mechanism that is distinct from traditional antianginal agents. It primarily inhibits the late sodium current (INa) in cardiac myocytes, which reduces intracellular sodium levels. This reduction leads to decreased calcium overload in the heart, ultimately improving myocardial oxygen balance. By doing so, ranolazine alleviates ischemic conditions without significantly affecting heart rate or blood pressure, making it a valuable option for patients with angina.

Pharmacological Properties

RANOL SR is classified as an antianginal agent. Its pharmacokinetics reveal that ranolazine is well-absorbed after oral administration, with peak plasma concentrations occurring approximately 2 to 5 hours post-dose. The drug exhibits extensive hepatic metabolism, primarily by cytochrome P450 3A4. The elimination half-life of ranolazine is approximately 7 hours, allowing for twice-daily dosing. Its pharmacological profile includes a favorable safety margin, as it does not significantly interact with adrenergic or calcium channel pathways.

Contraindications

RANOL SR is contraindicated in patients with known hypersensitivity to ranolazine or any of the excipients in the formulation. Additionally, it should not be used in patients with a history of liver cirrhosis or significant hepatic impairment, as these conditions can lead to increased plasma concentrations of the drug, heightening the risk of adverse effects. Co-administration with strong inhibitors of cytochrome P450 3A4, such as ketoconazole or clarithromycin, is also contraindicated due to the potential for serious drug interactions.

Side Effects

Common side effects associated with RANOL SR include dizziness, headache, constipation, and nausea. These effects are generally mild to moderate and often resolve with continued use. Serious side effects, although rare, may include QT interval prolongation, which can lead to arrhythmias. Patients should be monitored for any signs of cardiac irregularities, especially those with pre-existing conditions that may predispose them to such events. If any severe side effects occur, patients should seek medical attention immediately.

Dosage and Administration

The recommended starting dose of RANOL SR is typically 500 mg taken orally twice daily. Based on individual patient response and tolerability, the dose may be increased to a maximum of 1000 mg twice daily. It is advisable to take the medication with or without food, but consistency in relation to meals is recommended to maintain stable drug levels. Patients should be instructed to swallow the tablets whole and not to crush or chew them, as this may alter the drug’s release properties.

Interactions

RANOL SR has the potential to interact with various medications, particularly those that affect the cytochrome P450 enzyme system. Strong inhibitors of CYP3A4 can significantly increase ranolazine levels, leading to an increased risk of adverse effects. Conversely, inducers of CYP3A4 may decrease the efficacy of ranolazine. Additionally, caution should be exercised when using RANOL SR in conjunction with other drugs that prolong the QT interval, as this may further increase the risk of arrhythmias. It is essential for healthcare providers to review a patient’s complete medication list to avoid potential interactions.

Precautions

Before initiating treatment with RANOL SR, a thorough assessment of the patient’s medical history is crucial. Special precautions should be taken in patients with pre-existing renal or hepatic impairment, as these conditions may affect drug metabolism and clearance. Regular monitoring of renal function is recommended, especially in patients with moderate to severe renal impairment. Patients should also be advised to report any new or worsening symptoms, particularly those related to cardiac function, during treatment.

Clinical Studies

Clinical studies have demonstrated the efficacy of RANOL SR in reducing the frequency of angina episodes and improving exercise tolerance in patients with chronic stable angina. In a pivotal trial, ranolazine was shown to significantly reduce the number of angina attacks and the use of sublingual nitroglycerin compared to placebo. Furthermore, long-term studies have indicated that ranolazine is well-tolerated and maintains its efficacy over extended periods. The drug’s unique mechanism of action provides an alternative therapeutic option for patients who may not respond adequately to conventional antianginal therapies.

Conclusion

RANOL SR 80 MG represents a significant advancement in the management of chronic stable angina, offering a unique mechanism of action that complements existing treatment options. Its favorable pharmacological profile, combined with a manageable side effect profile, makes it a valuable choice for patients experiencing angina symptoms. As with any medication, it is essential for healthcare providers to assess individual patient needs and potential drug interactions to ensure safe and effective treatment.